Chicago, IL 的 頭頸部鱗狀細胞癌 臨床試驗
26 項針對 頭頸部鱗狀細胞癌 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
招募中3 期
- Advocate Illinois Masonic Medical Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Chicago Hospital, Chicago
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
招募中2/3 期
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #26, Chicago
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
招募中3 期
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
招募中3 期
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
招募中1/2 期
- The University of Chicago Medical Center (UCMC), Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Northwestern University, Chicago
- University of Illinois, Chicago
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
招募中2 期
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- Northwestern University Feinberg School of Medicine, Chicago
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
招募中觀察性研究
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
招募中1 期
- University of Chicago Medical Center /ID# 276638, Chicago
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
招募中2/3 期
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
招募中2 期
- Northwestern University, Chicago
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
招募中3 期
- Northwestern University, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
招募中1/2 期
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
招募中1/2 期
- The University of Chicago Medical Center - Oncology, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
招募中2 期
- University of Chicago Comprehensive Cancer Center, Chicago
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
招募中2/3 期
- The University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
招募中3 期
- University of Illinois Cancer Center, Chicago
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
招募中1 期
- The University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- The University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of Chicago, Chicago
其他城市的 頭頸部鱗狀細胞癌 試驗
- Houston, TX47 項研究
- Los Angeles, CA42 項研究
- Boston, MA40 項研究
- Nashville, TN39 項研究
- New York City, NY39 項研究
- St. Louis, MO28 項研究
- Arlington, VA26 項研究
- Philadelphia, PA26 項研究
- Atlanta, GA24 項研究
- San Antonio, TX22 項研究
- Pittsburgh, PA22 項研究
- New Haven, CT22 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌59 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肺癌41 項研究
- 肥胖症41 項研究
- 卵巢癌36 項研究
- 大腸直腸癌34 項研究
- 中風34 項研究
- 心臟衰竭31 項研究
- 過重29 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。